This is the third in a series of webinars, made possible through an unrestricted grant from Pfizer, Inc., involving a team of specialized physicians to provide education on the early diagnosis, treatment, and management of cardiac amyloidosis. There is an increasing appreciation that this disease is more prevalent than previously thought and there are newer therapies for the treatment which are important to consider in patient care. In this learning activity, challenging cases will be shared with experts to shed light on the complex issues in this disease and the role of echocardiography.

Originally Recorded April 29, 2021 | 12:00 - 1:15 PM ET

Moderator: Martha Grogan, MD

Speakers: Rodney Falk, MD; Michael Chetrit, MD; Ahmad Masri, MD, MS, and Allan Klein, MD, FASE

Learning Objectives:

1. Understand the challenges of identifying patients with cardiac amyloidosis and have strategies for differentiating cardiac amyloidosis from other causes of increased ventricular wall thickness.
2. Summarize the diagnostic evaluation for cardiac amyloidosis, including the differential diagnosis using echocardiography.
3. Demonstrate an understanding of the role of multi-modality imaging in the evaluation of cardiac amyloidosis. 

This activity is FREE for ASE Members and Nonmembers.

This activity offers 1.0 AMA PRA Category 1 Credit(s)™. 

The webinar is the third in a series of webinars supported by an unrestricted educational grant from Pfizer. The first two webinars are accessible as on-demand activities in the Learning Hub catalogue. 

Activity Expiration Date:  April 29, 2024.  CME/MOC points must be completed at this time.

Accreditation Statement:

The American Society of Echocardiography is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Echocardiography designates this article for 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is ASE’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM.  Physicians will earn MOC points equivalent to the amount of CME credits claimed for the activity.

ARDMS, CCI, Sonography Canada recognize ASE’s certificates and have agreed to honor the credit hours toward their registry requirements for sonographers.

Disclosures: 

According to ACCME policy, ASE implemented mechanisms to resolve all conflicts of interest prior to the planning and implementation of this activity.

The following moderators/speakers reported  relationships with one or more commercial interests:

• Ahmad Masri, MD, MS - Pfizer  (Research Grant); Akcea (Research Grant); Alnylam (Consultant/Advisor); Eidos (Consultant/Advisor); Ionis (Consultant/Advisor)
• Rodney Falk, MD - Alnylam (Consultant/Advisor); Ionis (Research Grant); Pfizer (Speakers/Speakers Bureau); Caelum (Board of Directors)
• Martha Grogan, MD Pfizer (Research Grant); Eidos (Research Grant); Alnylam (Research Grant)
• Michael Chetrit, MD - Alnylam (Consultant/Advisor)
• Allan Klein, MD, FASE - Pfizer (Consultant/Advisor)

The following moderators/speakers reported no actual or potential conflicts of interest in relation to this activity:

• None

The following CME reviewers and ASE Staff reported no actual or potential conflicts of interest in relation to this document: 

• Kathryn Lyons, ASE Healthcare Education Manager
• Renee Bullock-Palmer, MD, FASE
• Matthew Parker, MD, FASE

• Contact:
  ASE Learning Hub